Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 25 mg - tablet - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; microcrystalline cellulose; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; macrogol 400 - azathioprine is used as an immunosuppressant anti-metabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effects may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids.,azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants.,azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: ,? severe rheumatoid arthritis;,? systemic lupus erythematosus;,? dermatomyositis / polymyositis;,? autoimmune chronic active hepatitis;,? pemphigus vulgaris;,? polyarteritis nodosa;,? autoimmune haemolytic anaemia; ,? chronic refractory idiopathic thrombocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - hydroxychloroquine sulfate, quantity: 200 mg - tablet - excipient ingredients: hypromellose; colloidal anhydrous silica; calcium hydrogen phosphate; polysorbate 80; pregelatinised maize starch; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - rheumatoid arthritis; mild systemic and discoid lupus erythematosus; the suppression and treatment of malaria.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; titanium dioxide; hypromellose; iron oxide yellow; iron oxide red; iron oxide black; macrogol 400; macrogol 8000; sunset yellow fcf aluminium lake; carmine; indigo carmine aluminium lake - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis,/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia and chronic refractory idiopathic thromocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - belimumab, quantity: 400 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sucrose; citric acid monohydrate; polysorbate 80 - benlysta is indicated for:,add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre greater than or equal to 1:80 and/or anti-dsdna titre greater than or equal to 30 iu/ml) despite standard therapy.,treatment of active lupus nephritis in adult patients who are receiving standard therapy.,the safety and efficacy of benlysta have not been evaluated in patients with severe active central nervous system lupus.

Australia - English - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - belimumab, quantity: 120 mg - injection, powder for - excipient ingredients: sodium citrate dihydrate; sucrose; citric acid monohydrate; polysorbate 80 - benlysta is indicated for:,add-on therapy for reducing disease activity in adult patients with active, autoantibody-positive systemic lupus erythematosus (sle) with a high degree of disease activity (e.g. ana titre greater than or equal to 1:80 and/or anti-dsdna titre greater than or equal to 30 iu/ml) despite standard therapy.,treatment of active lupus nephritis in adult patients who are receiving standard therapy.,the safety and efficacy of benlysta have not been evaluated in patients with severe active central nervous system lupus.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; maize starch; povidone; croscarmellose sodium; sodium stearylfumarate; hypromellose; macrogol 400 - azathioprine is used as an immunosuppressant/antimetabolite either alone or, more commonly, in combination with the other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effects may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. azathioprine, in combination with corticosteroids and / or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis,/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 384.8 mg - tablet, enteric coated - excipient ingredients: crospovidone; maize starch; colloidal anhydrous silica; magnesium stearate; titanium dioxide; iron oxide red; hypromellose phthalate; iron oxide yellow; povidone; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - mycophenolate sodium, quantity: 192.4 mg - tablet, enteric coated - excipient ingredients: colloidal anhydrous silica; hypromellose phthalate; maize starch; indigo carmine; povidone; titanium dioxide; magnesium stearate; crospovidone; iron oxide yellow; lactose - myfortic is indicated for the prophylaxis of acute transplant rejection in adult patients receiving allogenic renal transplants. myfortic is indicated for induction and maintenance treatment of adult patients with who class iii, iv or v lupus nephritis. this indication is based on the evidence in literature reports of studies of treatment in patients with lupus nephritis, the majority of whom were isn/rps (2003) class iv. the evidence for efficacy was based on surrogate endpoints.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; maize starch; purified talc; povidone; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - azathioprine, quantity: 25 mg - tablet, film coated - excipient ingredients: purified talc; lactose monohydrate; magnesium stearate; maize starch; povidone; colloidal anhydrous silica; titanium dioxide; hypromellose; microcrystalline cellulose; peg-8 stearate - immunosuppressant antimetabolite: either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with higher dosage and prolonged usage of corticosteroids. azathioprine, in combination with cortocosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. azathioprine, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering from the following: severe rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis/polymyositis, autoimmune chronic active hepatitis, pemphigus vulgaris, polyarteritis nodosa, autoimmune haemolytic anaemia, chronic refractory idiopathic thrombocytopenic purpura.